Craft

Advanced
  • Home
  •  / Resverlogix
Resverlogix

Resverlogix

Stock Price

$0.1

2024-10-29

Market Capitalization

$18 M

2024-10-29

Resverlogix Summary

Company Summary

Overview
Resverlogix is a clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. It is engaged in epigenetics and develops apabetalone, a drug designed to regulate gene expression through the inhibition of bromodomain and extraterminal domain (BET) proteins.
Type
Public
Status
Active
Founded
2001
HQ
Calgary, CA | view all locations
Website
https://www.resverlogix.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Donald McCaffrey

    Donald McCaffrey, President & Chief Executive Officer, Chairman of the Board

    • Brad Cann

      Brad Cann, Chief Financial Officer

      • Michael Sweeney

        Michael Sweeney, Senior Vice President, Clinical Development

        • Henrik C. Hansen

          Henrik C. Hansen, Vice President, Intellectual Property

          LocationsView all

          2 locations detected

          • Calgary, AB HQ

            Canada

            4820 Richard Rd SW #300

          • San Francisco, CA

            United States

            44 Montgomery, 44 Montgomery St #4010, San Francisco

          Resverlogix Financials

          Summary Financials

          Gross profit (FY, 2025)
          $50.0K
          Net income (FY, 2025)
          ($7.8M)
          Cash (FY, 2025)
          $108.0K
          EBIT (FY, 2025)
          ($3.5M)
          Enterprise value
          $39.8M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX